A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01097577|
Recruitment Status : Completed
First Posted : April 1, 2010
Last Update Posted : June 22, 2010
Purpose: To compare the efficacy of pregabalin to placebo for postoperative pain control after photorefractive keratectomy.
Patients: Study subjects will be taken from a standard group of typical candidates for PRK surgery including active duty and DoD beneficiaries. Prior to being approached for the study, all patients will have had a previous desire for surgery and had a pre-operative evaluation indicating healthy ocular status.
Methods: Patients scheduled for PRK surgery will be briefed on the purpose of the study and invited to participate at the preoperative appointment. After the consent process, patients will be randomized in a 1:1 fashion to receive either oral pregabalin 75mg BID or placebo for pain control, in addition to the standard care treatment of as needed Percocet and tetracaine ophthalmic drops. Subjects will be evaluated daily for 4 days post-operatively for subjective pain assessment, adverse drug events and compliance, use of concomitant medications as well as monitoring of healing time. Quality of life will be measured at baseline and post-op day 2 when the peak of pain is anticipated. Analysis will be performed to detect an approximate 10% improvement in pain scores. Secondary outcomes will include measuring healing time, quality of life and use of rescue medications.
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Pain||Drug: pregabalin Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Comparison of Pregabalin (Lyrica®) to Placebo in Postoperative Pain Relief of Patients Status-post Photorefractive Keratectomy: A Double-masked Randomized Prospective Study|
|Study Start Date :||March 2010|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||June 2010|
1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
Other Name: Lyrica
|Placebo Comparator: lactose capsule||
1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
- Clinical Efficacy [ Time Frame: 5 days ]Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ).
- Clinical efficacy 2 [ Time Frame: 5 days ]Determine if there was a reduction in the need for use of rescue pain medications, Percocet and tetracaine, in those subjects who received pregabalin.
- Epithelial healing time [ Time Frame: 5 days or more ]Determine if there was a reduction in healing time associated with pregabalin as seen with daily slit-lamp observation.
- Quality of Life [ Time Frame: 5 days ]Determine if there was an improvement in the patient's functional health and well-being associated with pregabalin compared to standard of care as assessed by Brief Pain Inventory-short form (BPI-SF).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01097577
|United States, Texas|
|Wilford Hall Medical Center - Refractive Surgery Center|
|Lackland AFB, Texas, United States, 78236|
|Principal Investigator:||Julie M Meek, PharmD||Wilford Hall Medical Center|
|Study Chair:||Charles Reilly, MD||Wilford Hall Medical Center|
|Study Director:||Margaret Bonnie Rosbolt, PharmD, CCRC||Wilford Hall Medical Center|